savient pharmaceuticals inc (SVNT) Snapshot

Savient Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, revenues were $24,840,000 against $33,218,000 a year ago. Operating loss was $20,148,000 against $29,684,000 a year ago. Loss before income taxes was $26,688,000 against $34,198,000 a year ago. Net loss was $24,446,000 or $0.34 per basic and diluted share against $34,198,000 or $0.49 per basic and diluted share a year ago.

Savient Pharmaceuticals, Inc., Annual General Meeting, Jun 13, 2013., at 09:00 US Eastern Standard Time. Location: Bridgewater Marriott Hotel. Agenda: To elect as directors for one-year terms each of the seven nominees named in the attached proxy statement; to hold an advisory vote to approve executive compensation; to approve an amendment to 2011 Incentive Plan to increase the number of shares available for issuance under the plan; to ratify the appointment of KPMG LLP as independent registered public accountants for the fiscal year ending December 31, 2013; and to transact such other business as may properly come before the meeting or any adjournment thereof.

Savient Pharmaceuticals, Inc. announced consolidated earnings results for the fourth quarter and full year ended December 31, 2012. For the quarter, the company’s revenues product sales, net was $4,947,000 compared to $3,710,000 for the same period in 2011. Operating loss was $26,752,000 compared to $35,207,000 for the same period in 2011. Loss before income taxes was $28,034,000 compared to $38,589,000 for the same period in 2011. Net loss was $28,034,000 or $0.39 per basic and diluted share compared to $30,856,000 or $0.44 per basic and diluted share for the same period in 2011. For the full year, the company's revenues product sales, net was $18,023,000 compared to $9,565,000 for the same period in 2011. Operating loss was $119,098,000 compared to $115,436,000 for the same period in 2011. Loss before income taxes was $118,312,000 compared to $128,815,000 for the same period in 2011. Net loss was $118,312,000 or $1.67 per basic and diluted share compared to $102,027,000 or $1.46 per basic and diluted share for the same period in 2011.